The Supreme Court of India has informed the country’s central government that drug prices are too high and should not be raised again.
The criticism came during a Public Interest Litigation hearing, discussing the government’s newly proposed National Pharmaceuticals Pricing Policy.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The policy hopes to separate drug ceiling prices from bulk manufacturing costs, a move which critics claim would see the prices of essential drugs increase beyond the means of many people.
India’s Department of Chemicals and Petrochemicals confirmed that under the new policy, all 348 medicines on the country’s National List of Essential Medicines would come under price control instead of the 74 bulk drugs currently controlled.
The hearing was adjourned until 17 January 2012.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
